Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]

View source ↗

Summary

Phase 3 study of eplontersen in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloidosis with Cardiomyopathy
• Transthyretin-mediated Amyloid Cardiomyopathy

Drugs mentioned

• Eplontersen (eplontersen)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Status: COMPLETED